Literature DB >> 19798550

Modelling overdispersion and Markovian features in count data.

Iñaki F Trocóniz1, Elodie L Plan, Raymond Miller, Mats O Karlsson.   

Abstract

The number of counts (events) per unit of time is a discrete response variable that is generally analyzed with the Poisson distribution (PS) model. The PS model makes two assumptions: the mean number of counts (lambda) is assumed equal to the variance, and counts occurring in non-overlapping intervals are assumed independent. However, many counting outcomes show greater variability than predicted by the PS model, a phenomenon called overdispersion. The purpose of this study was to implement and explore, in the population context, different distribution models accounting for overdispersion and Markov patterns in the analysis of count data. Daily seizures count data obtained from 551 subjects during the 12-week screening phase of a double-blind, placebo-controlled, parallel-group multicenter study performed in epileptic patients with medically refractory partial seizures, were used in the current investigation. The following distribution models were fitted to the data: PS, Zero-Inflated PS (ZIP), Negative Binomial (NB), and Zero-Inflated Negative Binomial (ZINB) models. Markovian features were introduced estimating different lambdas and overdispersion parameters depending on whether the previous day was a seizure or a non-seizure day. All analyses were performed with NONMEM VI. All models were successfully implemented and all overdispersed models improved the fit with respect to the PS model. The NB model resulted in the best description of the data. The inclusion of Markovian features in lambda and in the overdispersion parameter improved the fit significantly (P < 0.001). The plot of the variance versus mean daily seizure count profiles, and the number of transitions, are suggested as model performance tools reflecting the capability to handle overdispersion and Markovian features, respectively.

Entities:  

Mesh:

Year:  2009        PMID: 19798550     DOI: 10.1007/s10928-009-9131-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

Authors:  E H Cox; C Veyrat-Follet; S L Beal; E Fuseau; S Kenkare; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

2.  Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.

Authors:  S K Gupta; G Sathyan; E A Lindemulder; P L Ho; L B Sheiner; L Aarons
Journal:  Clin Pharmacol Ther       Date:  1999-06       Impact factor: 6.875

3.  A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.

Authors:  M O Karlsson; R C Schoemaker; B Kemp; A F Cohen; J M van Gerven; B Tuk; C C Peck; M Danhof
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

4.  Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat.

Authors:  Daniël M Jonker; Rob A Voskuyl; Meindert Danhof
Journal:  Epilepsia       Date:  2004-05       Impact factor: 5.864

5.  Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures.

Authors:  Raymond Miller; Bill Frame; Brian Corrigan; Paula Burger; Howard Bockbrader; Elizabeth Garofalo; Richard Lalonde
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

6.  Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder.

Authors:  K Ito; Mm Hutmacher; J Liu; R Qiu; B Frame; R Miller
Journal:  Clin Pharmacol Ther       Date:  2008-02-06       Impact factor: 6.875

7.  Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Authors:  Per-Henrik Zingmark; Matts Kågedal; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.410

8.  A demonstration of modeling count data with an application to physical activity.

Authors:  Donald J Slymen; Guadalupe X Ayala; Elva M Arredondo; John P Elder
Journal:  Epidemiol Perspect Innov       Date:  2006-03-21
  8 in total
  19 in total

1.  Performance in population models for count data, part I: maximum likelihood approximations.

Authors:  Elodie L Plan; Alan Maloney; Iñaki F Trocóniz; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-04       Impact factor: 2.745

2.  Performance in population models for count data, part II: a new SAEM algorithm.

Authors:  Radojka Savic; Marc Lavielle
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-13       Impact factor: 2.745

3.  Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations.

Authors:  Chenhui Deng; Elodie L Plan; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-10       Impact factor: 2.745

Review 4.  Pharmacodynamic models for discrete data.

Authors:  Ines Paule; Pascal Girard; Gilles Freyer; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

5.  Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers.

Authors:  Ghada F Ahmed; Susan E Marino; Richard C Brundage; Serguei V S Pakhomov; Ilo E Leppik; James C Cloyd; Annie Clark; Angela K Birnbaum
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

6.  Pharmacometrics models with hidden Markovian dynamics.

Authors:  Marc Lavielle
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-08-31       Impact factor: 2.745

7.  A big data approach to the development of mixed-effects models for seizure count data.

Authors:  Joseph J Tharayil; Sharon Chiang; Robert Moss; John M Stern; William H Theodore; Daniel M Goldenholz
Journal:  Epilepsia       Date:  2017-03-30       Impact factor: 5.864

8.  Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology.

Authors:  Maud Delattre; Radojka M Savic; Raymond Miller; Mats O Karlsson; Marc Lavielle
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-04-29       Impact factor: 2.745

9.  Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.

Authors:  Nieves Vélez de Mendizábal; Dalia Vásquez-Bahena; Juan M Jiménez-Andrade; Mario I Ortiz; Gilberto Castañeda-Hernández; Iñaki F Trocóniz
Journal:  AAPS J       Date:  2012-09-12       Impact factor: 4.009

10.  Natural variability in seizure frequency: Implications for trials and placebo.

Authors:  Juan Romero; Phil Larimer; Bernard Chang; Shira R Goldenholz; Daniel M Goldenholz
Journal:  Epilepsy Res       Date:  2020-03-06       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.